Tucson-based MSDx Inc. said today it has received a grant of up to $75,000 grant from The Michael J. Fox Foundation for Parkinson’s Research to study the potential for a blood test to detect the early onset of Parkinson’s disease.
As part of the one-year Rapid Response Innovation Award, MSDx will study so-called “biomarkers” that can be used to diagnose and monitor Parkinson’s, the company said in a news release.
“Our mission is to provide a simple blood test for earlier diagnosis and long term monitoring of disease progression in a patient living with Parkinson’s, a disease that does not currently have biomarkers,” said Marie Wesselhoft, president of MSDx.
MSDx already is developing a blood test for multiple sclerosis.
The MSDx grant is entitled, “Neuromelanin in circulating phagocytes may reveal early neurodegeneration in Parkinson’s disease.”
The New York-based Michael J. Fox Foundation recently committed $10 million for its latest round of funding for its Edmond J. Safra Core Programs for Parkinson’s Disease Research.
MSDx is located at the the Arizona Center for Innovation, a business incubator at the University of Arizona Science and Technology Park.